Pharming Group Statistics
Total Valuation
Pharming Group has a market cap or net worth of 1.08 billion. The enterprise value is 1.04 billion.
| Market Cap | 1.08B |
| Enterprise Value | 1.04B |
Important Dates
The next estimated earnings date is Thursday, March 12, 2026.
| Earnings Date | Mar 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 685.15M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -2.65% |
| Shares Change (QoQ) | -26.83% |
| Owned by Insiders (%) | 2.77% |
| Owned by Institutions (%) | 20.80% |
| Float | 666.17M |
Valuation Ratios
The trailing PE ratio is 2,824.02 and the forward PE ratio is 34.41.
| PE Ratio | 2,824.02 |
| Forward PE | 34.41 |
| PS Ratio | 2.98 |
| PB Ratio | 4.08 |
| P/TBV Ratio | 8.32 |
| P/FCF Ratio | 20.46 |
| P/OCF Ratio | 20.23 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 20.42, with an EV/FCF ratio of 19.79.
| EV / Earnings | 2,730.71 |
| EV / Sales | 2.85 |
| EV / EBITDA | 20.42 |
| EV / EBIT | 25.35 |
| EV / FCF | 19.79 |
Financial Position
The company has a current ratio of 3.16, with a Debt / Equity ratio of 0.49.
| Current Ratio | 3.16 |
| Quick Ratio | 2.39 |
| Debt / Equity | 0.49 |
| Debt / EBITDA | 2.55 |
| Debt / FCF | 2.48 |
| Interest Coverage | 2.90 |
Financial Efficiency
Return on equity (ROE) is 0.03% and return on invested capital (ROIC) is 0.08%.
| Return on Equity (ROE) | 0.03% |
| Return on Assets (ROA) | 5.76% |
| Return on Invested Capital (ROIC) | 0.08% |
| Return on Capital Employed (ROCE) | 10.74% |
| Weighted Average Cost of Capital (WACC) | 4.94% |
| Revenue Per Employee | 896,718 |
| Profits Per Employee | 946 |
| Employee Count | 404 |
| Asset Turnover | 0.81 |
| Inventory Turnover | 0.57 |
Taxes
In the past 12 months, Pharming Group has paid 14.66 million in taxes.
| Income Tax | 14.66M |
| Effective Tax Rate | 99.53% |
Stock Price Statistics
The stock price has increased by +129.82% in the last 52 weeks. The beta is 0.23, so Pharming Group's price volatility has been lower than the market average.
| Beta (5Y) | 0.23 |
| 52-Week Price Change | +129.82% |
| 50-Day Moving Average | 1.03 |
| 200-Day Moving Average | 1.04 |
| Relative Strength Index (RSI) | 79.45 |
| Average Volume (20 Days) | 2,661 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Pharming Group had revenue of 362.27 million and earned 382,000 in profits. Earnings per share was 0.00.
| Revenue | 362.27M |
| Gross Profit | 325.70M |
| Operating Income | 41.46M |
| Pretax Income | 14.73M |
| Net Income | 382,000 |
| EBITDA | 47.91M |
| EBIT | 41.46M |
| Earnings Per Share (EPS) | 0.00 |
Balance Sheet
The company has 166.17 million in cash and 130.92 million in debt, with a net cash position of 35.25 million.
| Cash & Cash Equivalents | 166.17M |
| Total Debt | 130.92M |
| Net Cash | 35.25M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 264.64M |
| Book Value Per Share | 0.53 |
| Working Capital | 189.69M |
Cash Flow
In the last 12 months, operating cash flow was 53.33 million and capital expenditures -610,000, giving a free cash flow of 52.72 million.
| Operating Cash Flow | 53.33M |
| Capital Expenditures | -610,000 |
| Free Cash Flow | 52.72M |
| FCF Per Share | n/a |
Margins
Gross margin is 89.90%, with operating and profit margins of 11.44% and 0.11%.
| Gross Margin | 89.90% |
| Operating Margin | 11.44% |
| Pretax Margin | 4.06% |
| Profit Margin | 0.11% |
| EBITDA Margin | 13.23% |
| EBIT Margin | 11.44% |
| FCF Margin | 14.55% |
Dividends & Yields
Pharming Group does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 2.65% |
| Shareholder Yield | 2.65% |
| Earnings Yield | 0.04% |
| FCF Yield | 4.89% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Pharming Group has an Altman Z-Score of 2.65 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.65 |
| Piotroski F-Score | 6 |